nicorandil has been researched along with Cirrhosis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aboulhoda, BE; Ashour, H; El-Hanbuli, H; Harb, I; Mahmoud, H; Mostafa, A; Rashed, LA; Rashwan, E; Samir, M | 1 |
| Ashour, H; Elmorsy, S; Elsayed, MH; Harb, IA | 1 |
| Afzal, MZ; Beatka, MJ; Haberman, M; Lam, NT; Lawlor, MW; Strande, JL; Sullivan, RT | 1 |
| Araki, S; Izumiya, Y; Kaikita, K; Kojima, S; Matsubara, J; Nagayoshi, Y; Ogawa, H; Sakamoto, K; Sugiyama, S; Tsujita, K; Usuku, H | 1 |
| Chan, P; Chao, HH; Chen, PY; Cheng, TH; Hong, HJ; Liou, JY; Liu, JC; Sung, LC | 1 |
| Hirose, M; Kashihara, T; Matsumoto, K; Matsushita, N; Mende, U; Nakada, T; Nishio, A; Sato, F; Shimojo, H; Suzuki, S; Taira, E; Takeishi, Y; Yamada, M | 1 |
1 review(s) available for nicorandil and Cirrhosis
| Article | Year |
|---|---|
Hypothesis: The potential therapeutic role of nicorandil in COVID-19.
Topics: Anti-Inflammatory Agents; Anticoagulants; Antioxidants; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Fibrosis; Humans; Nicorandil; Pandemics; Pneumonia, Viral; Vasodilator Agents | 2020 |
5 other study(ies) available for nicorandil and Cirrhosis
| Article | Year |
|---|---|
Nicorandil mitigates amiodarone-induced pulmonary toxicity and fibrosis in association with the inhibition of lung TGF-β1/PI3K/Akt1-p/mTOR axis in rats.
Topics: Amiodarone; Animals; Fibrosis; Lung; Mammals; Nicorandil; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Rats; Sirolimus; TOR Serine-Threonine Kinases; Transforming Growth Factor beta1 | 2023 |
Cardioprotective effect of nicorandil on isoproterenol induced cardiomyopathy in the Mdx mouse model.
Topics: Animals; Cardiomyopathies; Disease Models, Animal; Female; Fibrosis; Isoproterenol; Mice, Inbred mdx; Muscular Dystrophy, Duchenne; Myocytes, Cardiac; NADPH Oxidases; Nicorandil; Reactive Oxygen Species; Stroke Volume; Superoxide Dismutase; Ventricular Function, Left; Xanthine Oxidase | 2021 |
Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angina Pectoris; Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cardiovascular Agents; Cells, Cultured; Chi-Square Distribution; Coronary Artery Disease; Cytokines; Disease Models, Animal; Drug Administration Schedule; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Endothelial Cells; Fibrosis; Humans; Inflammation Mediators; Japan; Lipids; Logistic Models; Macrophages; Male; Mice; Mice, Knockout; Middle Aged; Molecular Chaperones; Necrosis; Nicorandil; Odds Ratio; Retrospective Studies; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Nicorandil inhibits angiotensin-II-induced proliferation of cultured rat cardiac fibroblasts.
Topics: Angiotensin II; Animals; Animals, Newborn; Cardiotonic Agents; Cell Culture Techniques; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Endothelin-1; Fibroblasts; Fibrosis; Heart Ventricles; Nicorandil; Nitric Oxide; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2011 |
Nicorandil prevents Gαq-induced progressive heart failure and ventricular arrhythmias in transgenic mice.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomegaly; Electrocardiography; Female; Fibrosis; Gene Expression Regulation; GTP-Binding Protein alpha Subunits, Gq-G11; Heart Failure; KATP Channels; Mice; Mice, Transgenic; Myocardial Contraction; Myocardium; Nicorandil; Nitric Oxide Synthase; RNA, Messenger; TRPC Cation Channels; Ventricular Premature Complexes | 2012 |